Table 1.
Rationale for combinatorial approaches in the endometrial cancer space in an effort to expand checkpoint inhibition beyond biomarker select populations.
| Combination | Rationale |
|---|---|
| Immunotherapy + chemotherapy | Immune cell stimulation |
| Immunogenic cell death | |
| Enhanced presentation of tumor-specific antigens | |
| Increased T-cell activation by DCs | |
| Immunotherapy + antiangiogenic Therapy | Reduction in Treg activity |
| Reversal of immunosuppressive effects of VEGF | |
| Improved T-cell trafficking and infiltration of CD8+ T-cells and macrophages into the tumor bed | |
| Increased immune cell recruitment | |
| Immunotherapy + PARPi | Increased TILs |
| Enhance DNA damage, with increased CD8+ T-cells | |
| Potential synergy with PARPi |
DC, Dendritic Cells; PARPi, poly (ADP-ribose) polymerase inhibitor; TIL, Tumor Infiltrating Lymphocytes; Treg, regulatory T-cell; VEGF, vascular endothelial growth factor.